Difficulties in diagnosing angiomatoid fibrous histiocytoma of the head and neck region: A case report

doi:10.12998/wjcc.v11.i26.6252

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 26

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3010)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series, Tables (1-4) series.

Item

Count

PDF

WORD

HTML

1392

Figures (1-7)

330

Tables (1-4)

207

Sum=2017

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

192

Download

334

Sum=526

Publishing Process of This Article

Item

Count

Browse

119

Download

227

Sum=346

Sep 16, 2023 (publication date) through Nov 28, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Sep 16, 2023; 11(26): 6252-6261
Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6252

Table 3 Relevant therapeutics for gene MRE11

Drug name	Tumor entity	Approval	Approval limited to biomarkers/others	Approval in combination with other drugs
Niraparib, PARP inhibitor	Prostate cancer	EMA	BRCA1, BRCA2	Abiraterone
Olaparib, PARP inhibitor	Fallopian tube carcinoma	EMA	HRD	Bevacizumab
Olaparib, PARP inhibitor	Fallopian tube carcinoma	FDA	HRD	Bevacizumab
Olaparib, PARP inhibitor	Ovarian cancer	EMA	Cancer associated with HRD	Bevacizumab
Olaparib, PARP inhibitor	Ovarian cancer	FDA	HRD	Bevacizumab
Olaparib, PARP inhibitor	Primary peritoneal carcinoma	EMA	Cancer associated with HRD	Bevacizumab
Olaparib, PARP inhibitor	Primary peritoneal carcinoma	FDA	HRD	Bevacizumab
Olaparib, PARP inhibitor	Prostate cancer	EMA	Adult patients, metastatic castraction- resitant cancer, chemotherapy not indicated	Abiraterone, prednisone
Olaparib, PARP inhibitor	Prostate cancer	FDA	BRCA1, BRCA2	Abiraterone, prednisone

BRCA1: Breast cancer type 1 susceptibility protein; BRCA2: Breast cancer type 2 susceptibility protein; HRD: Cancer associated with Homologous Recombination Deficiency.

Citation: Michcik A, Bień M, Wojciechowska B, Polcyn A, Garbacewicz Ł, Kowalski J, Drogoszewska B. Difficulties in diagnosing angiomatoid fibrous histiocytoma of the head and neck region: A case report. World J Clin Cases 2023; 11(26): 6252-6261
URL: https://www.wjgnet.com/2307-8960/full/v11/i26/6252.htm
DOI: https://dx.doi.org/10.12998/wjcc.v11.i26.6252